Free Trial

Dominari (DOMH) Competitors

Dominari logo
$5.26 +0.01 (+0.19%)
As of 12:30 PM Eastern

DOMH vs. XOMA, LXRX, VSTM, VNDA, CDXS, AGEN, ACHV, IRWD, SGMO, and FBIO

Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA Royalty (XOMA), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Agenus (AGEN), Achieve Life Sciences (ACHV), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry.

Dominari vs. Its Competitors

XOMA Royalty (NASDAQ:XOMA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by company insiders. Comparatively, 33.0% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XOMA Royalty currently has a consensus price target of $69.50, indicating a potential upside of 158.85%. Given XOMA Royalty's stronger consensus rating and higher possible upside, equities analysts plainly believe XOMA Royalty is more favorable than Dominari.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

XOMA Royalty has higher revenue and earnings than Dominari. XOMA Royalty is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA Royalty$28.49M11.28-$13.82M-$1.15-23.35
Dominari$18.15M4.24-$14.70M-$4.50-1.17

In the previous week, XOMA Royalty had 7 more articles in the media than Dominari. MarketBeat recorded 7 mentions for XOMA Royalty and 0 mentions for Dominari. XOMA Royalty's average media sentiment score of 0.54 beat Dominari's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Royalty Positive
Dominari Neutral

XOMA Royalty has a net margin of -13.04% compared to Dominari's net margin of -167.73%. XOMA Royalty's return on equity of -12.43% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA Royalty-13.04% -12.43% -4.85%
Dominari -167.73%-91.67%-77.80%

XOMA Royalty has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Summary

XOMA Royalty beats Dominari on 14 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOMH vs. The Competition

MetricDominariMED IndustryMedical SectorNASDAQ Exchange
Market Cap$77.01M$2.42B$5.50B$9.03B
Dividend YieldN/A1.77%5.39%4.11%
P/E Ratio-1.178.9627.5220.10
Price / Sales4.24468.23397.84108.06
Price / CashN/A151.5836.1356.90
Price / Book0.924.627.985.65
Net Income-$14.70M$31.34M$3.16B$248.47M
7 Day Performance-10.85%0.65%1.91%2.80%
1 Month Performance21.20%7.60%4.17%5.62%
1 Year Performance161.69%1.55%35.76%21.20%

Dominari Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DOMH
Dominari
0.9665 of 5 stars
$5.26
+0.2%
N/A+163.8%$77.01M$18.15M-1.174Gap Up
XOMA
XOMA Royalty
4.432 of 5 stars
$27.27
+4.0%
$69.50
+154.9%
+6.0%$328.09M$28.49M-23.8310Gap Up
LXRX
Lexicon Pharmaceuticals
2.4912 of 5 stars
$0.75
+1.8%
$3.67
+390.9%
-42.8%$270.03M$31.08M-1.46140News Coverage
VSTM
Verastem
2.8331 of 5 stars
$4.88
+5.5%
$13.63
+179.5%
+65.2%$266.78M$10K-1.5250
VNDA
Vanda Pharmaceuticals
4.6272 of 5 stars
$4.50
+0.7%
$16.50
+266.7%
-7.2%$265.72M$198.77M-6.01290
CDXS
Codexis
3.6851 of 5 stars
$2.49
+5.5%
$11.00
+341.8%
-2.8%$205.04M$49.82M-2.50250Positive News
AGEN
Agenus
4.3134 of 5 stars
$5.02
+4.6%
$14.00
+178.9%
-61.4%$137.27M$103.46M-0.58440
ACHV
Achieve Life Sciences
1.603 of 5 stars
$3.75
-2.2%
$14.33
+281.8%
-50.8%$128.87MN/A-2.7720
IRWD
Ironwood Pharmaceuticals
4.792 of 5 stars
$0.69
+2.0%
$4.78
+596.3%
-88.1%$110.52M$351.41M-3.41220
SGMO
Sangamo Therapeutics
2.7396 of 5 stars
$0.47
+7.6%
$4.50
+867.7%
+67.1%$107.49M$57.80M-1.18480
FBIO
Fortress Biotech
2.6117 of 5 stars
$1.73
+0.9%
$21.00
+1,117.4%
+9.6%$51.01M$57.67M-0.77170Gap Up

Related Companies and Tools


This page (NASDAQ:DOMH) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners